Intravitreal ranibizumab (lucentis) for whole brain radiotherapy-induced maculopathy.

摘要

This large series confirms, in a standard practice setting, similar efficacy and tolerability of treatment as previously reported in our phase I-II study. The benefit to patients with a gross tumour volume >48?cm(3) may be limited.